Nuvation Bio Inc. (NUVB) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Cash cushion • Profitability rebound • Rich valuation NUVB showed a sharp Q1 2026 turnaround with strong liquidity, high gross margins, and positive cash flow, but its full-year loss history and rich sales-based valuation still demand consistent execution.
Price Behavior
Key Price Behavior Insights: • Support holding • Breakout pressure • Volatile rebound Support Level: $4.69–$4.75 Resistance Level: $5.15–$5.20 NUVB has rebounded into the upper half of its recent range over the last month, with $4.69–$4.75 acting as support and $5.15–$5.20 as resistance, but the latest pullback shows the breakout remains unconfirmed.
Sentiment & News
Key News Insights: • Shareholder investigation • U.S. manufacturing • QoL gains Nuvation Bio's May 2026 updates combined shareholder legal scrutiny with active investor outreach, IBTROZI manufacturing progress, and encouraging TRUST-II quality-of-life data.
AI Summary
NUVB has shifted from a pure clinical optionality story to a real commercial execution test now that IBTROZI is generating meaningful revenue and profitability, but with adoption still early, valuation rich, and legal/governance overhangs in place, the key question is whether this launch can sustain and scale before the market re-rates it.
Description
Nuvation Bio is a clinical-stage biopharmaceutical company developing small-molecule therapies for oncology, with its lead candidate NUV-422 targeting CDK2, CDK4 and CDK6. Its pipeline also includes oral inhibitors affecting BET proteins, Wee1 kinase, and adenosine receptors, along with a drug–drug conjugate platform that pairs PARP inhibition with cytotoxic warheads to treat cancers including ER+ breast and ovarian tumors. The company was founded in 2018, rebranded from RePharmation in 2019, and is based in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 5 | Jan 12 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop. | Closed | -24.8% |
| Sep 15 | Sep 22 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s near-term FDA approval and early commercial launch of IBTROZI™, strong cash runway, and positive technical signals with a 13.8% gain over three weeks establish it as a hot idea, balanced with caution on volatility and rising leverage risks before more commercial data emerge. | Closed | +3.8% |